These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 15162797

  • 21. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.
    Groulx I, Lee S.
    Mol Cell Biol; 2002 Aug; 22(15):5319-36. PubMed ID: 12101228
    [Abstract] [Full Text] [Related]

  • 22. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU.
    Cancer Res; 2001 Jul 01; 61(13):5215-22. PubMed ID: 11431362
    [Abstract] [Full Text] [Related]

  • 23. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression.
    Jensen RL, Gillespie D, House P, Layfield L, Shelton C.
    J Neurosurg; 2004 Mar 01; 100(3):488-97. PubMed ID: 15035285
    [Abstract] [Full Text] [Related]

  • 24. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 25. The von Hippel-Lindau tumor suppressor protein.
    Ivan M, Kaelin WG.
    Curr Opin Genet Dev; 2001 Feb 04; 11(1):27-34. PubMed ID: 11163147
    [Abstract] [Full Text] [Related]

  • 26. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor.
    Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, Kondo K, Yoshida M, Yamashita A, Kishida T, Nakaigawa N, Nagashima Y, Kubota Y, Yao M, Ohno S.
    Oncogene; 2003 May 08; 22(18):2728-38. PubMed ID: 12743597
    [Abstract] [Full Text] [Related]

  • 27. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.
    Cancer Res; 2004 Dec 01; 64(23):8595-603. PubMed ID: 15574766
    [Abstract] [Full Text] [Related]

  • 28. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 29. Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter.
    Zatyka M, Morrissey C, Kuzmin I, Lerman MI, Latif F, Richards FM, Maher ER.
    J Med Genet; 2002 Jul 15; 39(7):463-72. PubMed ID: 12114475
    [Abstract] [Full Text] [Related]

  • 30. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma.
    Choi JW, Park SC, Kang GH, Liu JO, Youn HD.
    Cancer Res; 2004 Jan 01; 64(1):35-9. PubMed ID: 14729605
    [Abstract] [Full Text] [Related]

  • 31. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia.
    Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, Prchal JF, Prchal JT.
    Am J Hum Genet; 2003 Aug 01; 73(2):412-9. PubMed ID: 12844285
    [Abstract] [Full Text] [Related]

  • 32. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
    Corn PG, McDonald ER, Herman JG, El-Deiry WS.
    Nat Genet; 2003 Nov 01; 35(3):229-37. PubMed ID: 14556007
    [Abstract] [Full Text] [Related]

  • 33. A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.
    Iida K, Okimura Y, Takahashi K, Inomata S, Iguchi G, Kaji H, Chihara K.
    Int J Mol Med; 2004 Mar 01; 13(3):401-4. PubMed ID: 14767570
    [Abstract] [Full Text] [Related]

  • 34. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Richards FM, Johnson CM, Maher ER.
    Oncogene; 2005 Jun 30; 24(28):4549-58. PubMed ID: 15824735
    [Abstract] [Full Text] [Related]

  • 35. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M.
    Mol Cell Biol; 2004 Apr 30; 24(8):3251-61. PubMed ID: 15060148
    [Abstract] [Full Text] [Related]

  • 36. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI, Okuda H, Takaki Y, Baba M, Hirai S, Ohno S, Shuin T.
    Oncol Rep; 2005 Jun 30; 13(6):1033-41. PubMed ID: 15870918
    [Abstract] [Full Text] [Related]

  • 37. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
    Palayoor ST, Burgos MA, Shoaibi A, Tofilon PJ, Coleman CN.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4158-64. PubMed ID: 15217953
    [Abstract] [Full Text] [Related]

  • 38. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
    Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ.
    Oncogene; 2000 Dec 14; 19(54):6297-305. PubMed ID: 11175344
    [Abstract] [Full Text] [Related]

  • 39. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP.
    Sang N, Fang J, Srinivas V, Leshchinsky I, Caro J.
    Mol Cell Biol; 2002 May 14; 22(9):2984-92. PubMed ID: 11940656
    [Abstract] [Full Text] [Related]

  • 40. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C, Moore JW, Robertson N, Harris AL.
    Cancer Res; 2001 Oct 01; 61(19):7349-55. PubMed ID: 11585776
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.